These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18641842)

  • 21. The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy.
    Sorrentino FS; Allkabes M; Salsini G; Bonifazzi C; Perri P
    Life Sci; 2016 Oct; 162():54-9. PubMed ID: 27497914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A central role for inflammation in the pathogenesis of diabetic retinopathy.
    Joussen AM; Poulaki V; Le ML; Koizumi K; Esser C; Janicki H; Schraermeyer U; Kociok N; Fauser S; Kirchhof B; Kern TS; Adamis AP
    FASEB J; 2004 Sep; 18(12):1450-2. PubMed ID: 15231732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The evaluation of color vision and its diagnostic value in predicting the risk of diabetic retinopathy in patients with glucose metabolism disorders].
    Jończyk-Skórka K; Kowalski J
    Pol Merkur Lekarski; 2017 Jul; 43(253):15-21. PubMed ID: 28805196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential role of PKC beta in diabetic retinopathy and macular edema.
    Aiello LP
    Surv Ophthalmol; 2002 Dec; 47 Suppl 2():S263-9. PubMed ID: 12507628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives.
    Simó R; Hernández C;
    Trends Endocrinol Metab; 2014 Jan; 25(1):23-33. PubMed ID: 24183659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glial cell alterations in diabetes-induced neurodegeneration.
    Llorián-Salvador M; Cabeza-Fernández S; Gomez-Sanchez JA; de la Fuente AG
    Cell Mol Life Sci; 2024 Jan; 81(1):47. PubMed ID: 38236305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy.
    de Moraes G; Layton CJ
    Clin Exp Ophthalmol; 2016 Dec; 44(9):838-852. PubMed ID: 27334889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes.
    Feit-Leichman RA; Kinouchi R; Takeda M; Fan Z; Mohr S; Kern TS; Chen DF
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4281-7. PubMed ID: 16249509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing blindness due to diabetic retinopathy. Control glycaemia and blood pressure, and monitor the eyes.
    Prescrire Int; 2010 Feb; 19(105):35-8. PubMed ID: 20455344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurodegeneration in diabetic retinopathy: Potential for novel therapies.
    Barber AJ; Baccouche B
    Vision Res; 2017 Oct; 139():82-92. PubMed ID: 28988945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progress of research on pathogenesis and medical treatment of diabetic retinopathy].
    Geng S; Ye JJ
    Zhonghua Yan Ke Za Zhi; 2008 Jan; 44(1):76-81. PubMed ID: 18510248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early photocoagulation in patients with either type I or type II diabetes.
    Ferris F
    Trans Am Ophthalmol Soc; 1996; 94():505-37. PubMed ID: 8981711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New concepts in pathogenesis and treatment of diabetic retinopathy.
    Spranger J; Pfeiffer AF
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S438-50. PubMed ID: 11460590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lowering the risk of visual impairment and blindness.
    Cunha-Vaz J
    Diabet Med; 1998; 15 Suppl 4():S47-50. PubMed ID: 9868992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms of diabetic retinopathy: potential therapeutic targets.
    Coucha M; Elshaer SL; Eldahshan WS; Mysona BA; El-Remessy AB
    Middle East Afr J Ophthalmol; 2015; 22(2):135-44. PubMed ID: 25949069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The state of ocular neurosensory apparatus in diabetes mellitus].
    Sdobnikova SV; Kulybysheva VS; Sidamonidze AL
    Vestn Oftalmol; 2018; 134(5. Vyp. 2):263-269. PubMed ID: 30499527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group.
    Lieth E; Barber AJ; Xu B; Dice C; Ratz MJ; Tanase D; Strother JM
    Diabetes; 1998 May; 47(5):815-20. PubMed ID: 9588455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurodegeneration and neuroprotection in diabetic retinopathy.
    Ola MS; Nawaz MI; Khan HA; Alhomida AS
    Int J Mol Sci; 2013 Jan; 14(2):2559-72. PubMed ID: 23358247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlation analysis between diabetic retinopathy and early atherosclerotic changes in adolescents with type 1 diabetes -- preliminary report].
    Głowińska-Olszewska B; Urban M; Urban B; Tołwińska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(2):96-102. PubMed ID: 16813713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic retinopathy: a growing concern in an aging population.
    Paulus YM; Gariano RF
    Geriatrics; 2009 Feb; 64(2):16-20. PubMed ID: 19256582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.